Apotex Inc. v. Sanofi-Aventis, (2013) 447 N.R. 313 (FCA)
Linked as:
Extract
Apotex Inc. v. Sanofi-Aventis, (2013) 447 N.R. 313 (FCA)
No longer available (Autolink)
See the full content of this document
This document cites
- Sanofi-Synthelabo Canada Inc. et al. v. Apotex Inc. et al., (2008) 381 N.R. 125 (SCC)
- AstraZeneca Canada Inc. et al. v. Mylan Pharmaceuticals ULC et al., (2012) 432 N.R. 292 (FCA)
- Allergan Inc. et al. v. Canada (Minister of Health) et al., (2012) 440 N.R. 269 (FCA)
- Pfizer Canada Inc. et al. v. Novopharm Ltd. et al., (2012) 436 N.R. 299 (SCC)
- Pfizer Canada Inc. et al. v. Mylan Pharmaceuticals ULC et al., (2012) 430 N.R. 326 (FCA)
